Loading clinical trials...
Loading clinical trials...
Evaluation of Valproic Acid (VPA) as Adjunctive Therapy for Liver Transplant Patients With Moderate to Severe Hemorrhage at Risk of Ischemia Reperfusion (I/R) Injury
Conditions
Interventions
Valproic acid
Isotonic saline solution
Locations
4
United States
University of California San Francisco
San Francisco, California, United States
University of Colorado - Denver
Denver, Colorado, United States
University of Texas Southwest
Dallas, Texas, United States
Houston Methodist Specialty and Transplant Hospital
Houston, Texas, United States
Start Date
January 1, 2022
Primary Completion Date
June 1, 2023
Completion Date
June 1, 2023
Last Updated
October 29, 2021
NCT05806645
NCT07472426
NCT07447791
NCT07106151
NCT07418242
NCT05879432
Lead Sponsor
Westat
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions